Designing the Future: Trials in Motion

New to this year’s Congress, Designing the Future: Trials in Motion is a dynamic session where SIU 2025 invites investigators to share clinical trials that are actively shaping the future of urologic care. This session will highlight trials that are about to launch, currently enrolling, or in follow-up, but yet to report out — spotlighting innovative designs and compelling scientific rationales. These presentations will offer a global platform to engage with peers and spark collaboration. Submissions should focus on trial design, objectives, and eligibility criteria, emphasizing the potential impact these trials may have on tomorrow’s practice.

Important Dates*

Submission Deadline	Wednesday, August 6, 2025
Notifications Sent to Presenting Author	Wednesday, August 27, 2025
Deadline for the presenting author to respond to the invitation and register	Wednesday, September 17, 2025
Session Date	Saturday, November 1, 2025

*subject to change

Registration

The presenting author of each accepted submission must attend the SIU 2025 Congress in person in Edinburgh.
Presenters must confirm their participation and complete their registration for SIU 2025 by Wednesday, September 17, 2025.
Failure to register by the deadline will result in removal from the programme. Presenting authors may be changed up until the deadline, but any replacement must also be registered to attend. After this date, unavailability to present onsite will lead to automatic withdrawal.

Submission Guidelines

Eligible Studies & Acceptable Trial Types:

✅ Trials in progress from phase 1, 2, and 3 are eligible.
✅ Industry-sponsored and investigator-initiated trials are both accepted.
🧪 Trials may be:

About to launch
Actively recruiting
In follow-up

📄 Submissions should outline:

The trial’s purpose, design, and eligibility criteria
No preliminary data or results should be included.

Requirements:

✅ Trials must be registered and currently open to patient enrolment.
❌ No interim data or results may be included.
❌ Proprietary drug names and manufacturer names are not allowed.
❌ No references to pricing, fees, or reimbursement information are permitted.

Publication

This session is intended solely for informational and educational purposes regarding active clinical trials. Please note that any submissions or abstracts presented will not be published in the SIUJ.

Submissions Field Requirements

All fields are mandatory.
Ensure the accuracy of all submitted information, as post-submission modifications will not be permitted.

Category

Adrenals
Basic Science - Benign Diseases
Bladder Cancer - Basic Science
Bladder Cancer - Clinical
BPO/LUTS
Female Urology
History of Medicine
Infections and Inflammatory Diseases
Infertility
Kidney and Ureter, Benign Diseases
Kidney and Ureteral Cancer - Basic Science
Kidney and Ureteral Cancer - Clinical
Minimally Invasive Surgery/Robotics
Pediatric Urology
Penis/Testis/Urethra: Cancer - Basic Science
Penis/Testis/Urethra: Cancer - Clinical
Penis/Testis: Benign Disease
Prostate Cancer - Basic Science
Prostate Cancer - Detection
Prostate Cancer - Clinical Localized
Prostate Cancer - Clinical Advanced
Reconstruction
Renal Transplantation
Sexual Dysfunction
Stones
Evaluation & Medical Management
Surgical Treatment
Training and Education
Trauma
Voiding Dysfunction
Other

Submission Title

Limited to 100 characters (approximately 15 words).

Background

Limited to 1200 characters (approximately 200 words).
Should include:
Scientific rationale
Overview of interventions
Description of any related correlative studies

Methods

Limited to 2600 characters (approximately 350 words).
Should include:
Trial design and statistical approach, highlighting innovative elements.
Planned treatments or interventions.
Key eligibility criteria, especially any novel aspects.
Current enrolment status (without reporting outcomes or endpoints).
Phase 2/3 trials: indicate the number of patients enrolled to date.
Phase 3 trials: may include recent data monitoring committee review updates

Trial Phase - Phase 1, 2 or 3.

Trial Sponsor

Clinical Trial Identifier Number

Presenting Author – (NOTE: All communication will be with the presenting author.)

First name
Last name
Institution/Affiliation
Email Address
- Ensure this email address is valid as all communication will be sent to the presenting author by email.)
Cell Phone #

Co-Authors

Include First Name, Last Name, Email, and Affiliation

Who Can Present

✅ Only trial investigators may present on behalf of a study.
🚫 Industry representatives are not permitted to present.

Review Criteria

Scientific Merit – Does the study explore a significant and novel clinical question?
Study Design – Are methodology and endpoints clearly articulated and appropriate?
Collaboration Potential – Is there evidence of multicentre or multidisciplinary collaboration?
Relevance – Is the topic of interest to the SIU 2025 community?

Presentation Details

Presenters will be allocated approximately 10 minutes to share their study and engage with the audience – 4-minute presentation, 6-minute discussion/Q&A.
Presentations will be made in English.